RAPIBLYK
GrowthSMlandiolol
NDAINTRAVENOUSPOWDER
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RAPIBLYK (landiolol) is an intravenous beta-blocker approved in November 2024 for acute cardiovascular indications requiring rapid-onset heart rate control. Landiolol is an ultra-short-acting selective beta-1 adrenergic antagonist designed for perioperative and acute care settings. The drug works by blocking beta-1 receptors to reduce heart rate and myocardial oxygen demand in hemodynamically sensitive patients.
Growth8.0 years to LOE
Early-stage product in growth phase with zero current competitive intensity; expect rapid team expansion and market development roles as hospital adoption accelerates.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RAPIBLYK represents a rare market-entry opportunity in a nascent competitive segment with zero current rivals; early-career professionals joining the team now will shape market definition and gain hands-on experience in hospital-based product launches. The 8-year patent window and acute-care focus position this as a stable, growth-oriented assignment with strong visibility into expansion strategies.
Hospital/Health System Account Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.